Zafgen (ZFGN) vs. Its Rivals Head to Head Survey

Zafgen (NASDAQ: ZFGN) is one of 284 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Zafgen to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Zafgen and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Zafgen N/A -$57.87 million -2.03
Zafgen Competitors $290.00 million $35.57 million 146.42

Zafgen’s competitors have higher revenue and earnings than Zafgen. Zafgen is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Zafgen has a beta of -1.34, meaning that its share price is 234% less volatile than the S&P 500. Comparatively, Zafgen’s competitors have a beta of 1.01, meaning that their average share price is 1% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Zafgen and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zafgen 0 1 1 0 2.50
Zafgen Competitors 793 3136 11403 229 2.71

Zafgen currently has a consensus price target of $9.00, indicating a potential upside of 146.58%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.50%. Given Zafgen’s higher probable upside, research analysts clearly believe Zafgen is more favorable than its competitors.

Insider and Institutional Ownership

48.4% of Zafgen shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.2% of Zafgen shares are owned by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Zafgen and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zafgen N/A -46.88% -43.31%
Zafgen Competitors -5,359.54% -437.67% -40.48%


Zafgen competitors beat Zafgen on 8 of the 12 factors compared.

Zafgen Company Profile

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with's FREE daily email newsletter.

Leave a Reply